TD Cowen Maintains Buy on Avidity Biosciences, Raises Price Target to $78
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Ritu Baral maintains a Buy rating on Avidity Biosciences (NASDAQ:RNA) and raises the price target from $56 to $78.
October 21, 2024 | 5:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen analyst Ritu Baral has reaffirmed a Buy rating for Avidity Biosciences and increased the price target from $56 to $78, indicating a positive outlook for the stock.
The reaffirmation of a Buy rating and a significant increase in the price target from $56 to $78 by a reputable analyst suggests a strong positive sentiment towards Avidity Biosciences. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100